Postdoctoral Scientist – Fibrosis, Liver Disease jobs in United States
cer-icon
Apply on Employer Site
company-logo

Gilead Sciences · 6 hours ago

Postdoctoral Scientist – Fibrosis, Liver Disease

Gilead Sciences is committed to creating a healthier world by developing therapies for serious diseases. The Postdoctoral Scientist role focuses on innovative research in chronic fibrotic liver disease, leading independent projects to uncover novel pathogenic mechanisms and therapeutic targets.

BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

The successful candidate will initiate and lead independent research projects to investigate pathogenic mechanisms in chronic fibrotic liver disease
They will utilize Gilead’s rich single cell and spatial transcriptomic datasets as well as clinical datasets to uncover novel mechanisms driving fibrotic niche expansion
The candidate will use a combination of mouse genetic and pharmacology approaches to investigate key disease drivers and establish novel ex vivo models allowing for target identification and screening
With the support of a mentor, the postdoctoral scientist will design, conduct, and analyze in vitro and in vivo experiments to drive research towards publication in a top-tier journal
The postdoctoral scientist will be expected to publish their work in top-tier journals and present at scientific conferences
The selected candidate will work in a highly collaborative environment at Gilead through a three-year fixed term, with access to world-class research facilities and the opportunity to leverage expertise and resources across multiple functional areas

Qualification

Ph.D. in biochemistryMammalian cell biologyBiochemistry techniquesMouse models of diseaseCRISPR/Cas9Single-cell transcriptomicsFlow cytometryCollaborative team environmentCommunication skillsOrganizational skills

Required

Ph.D. in biochemistry, molecular biology, immunology or related discipline
At least one first author paper published or accepted in a peer-reviewed journal
Proficiency in mammalian cell biology and biochemistry techniques
Excellent written, verbal, and interpersonal communication skills and strong organizational skills are required

Preferred

Preference will be given to candidates with broad hands-on expertise in cell biology, molecular biology, biochemistry and imaging techniques including in vitro cell-based functional assays, primary cell cultures, transfection/transduction techniques, CRISPR/Cas9, microscopy, flow cytometry, and other immunoassays
Hands-on experience with mouse models of disease, mouse handling, in-life procedures and tissue harvesting are preferred
Familiarity with the analysis of large-scale multiomic datasets, such as single-cell and spatial transcriptomics, is preferred
Experience developing complex primary cell co-culture systems is an advantage
The individual should have demonstrable skills and experience in leading focused hypothesis-driven biological research, as exemplified by quality publications
The successful candidate must have demonstrated success in working in a cross-functional and highly collaborative team environment, and must be able to communicate clearly and effectively, both verbally and in writing, to a variety of audiences

Benefits

Company-sponsored medical, dental, vision, and life insurance plans

Company

Gilead Sciences

company-logo
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.

H1B Sponsorship

Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (269)
2024 (241)
2023 (222)
2022 (208)
2021 (235)
2020 (187)

Funding

Current Stage
Public Company
Total Funding
$4.41B
Key Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B

Leadership Team

leader-logo
Keeley Wettan
Senior Vice President, Legal
linkedin
leader-logo
Patrick Loerch
Senior Vice President, Clinical Data Science
linkedin
Company data provided by crunchbase